The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy
- 1 April 2013
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 86 (1) , 42-51
Abstract
No abstract availableKeywords
This publication has 77 references indexed in Scilit:
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate CancerJournal of Urology, 2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adultsCritical Reviews in Oncology/Hematology, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI: Journal of the National Cancer Institute, 2009
- Management of complications of androgen deprivation therapy in the older manCritical Reviews in Oncology/Hematology, 2009
- Metabolic Complications of Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletionNature Reviews Endocrinology, 2009
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate CancerUrology, 2008